



**FOR IMMEDIATE RELEASE**

**Contacts:**

**For Ohmx Corporation:**

Dimitra Georganopoulou  
 Tel: (847) 491-8513  
 Fax: (847) 491-8510  
 dimitra@ohmx.com

**Ohmx Announces Participation in Investment Conferences**

**Evanston IL, November 4<sup>th</sup> 2010** – Ohmx Corporation, a bioelectronic detection company focused on developing a near-patient analyzer for monitoring of chronic diseases, is pleased to announce its participation in upcoming investment conferences, as shown in the table below. If you are attending any of these events, please take the opportunity to see our presentation, or contact us so we can arrange for a private meeting to discuss our technology and current business strategy.

<b>Event:</b>	<b>Location:</b>	<b>Date:</b>
<b>Entrepreneurship Pitch Challenge*</b>	Evanston, IL	March 2011
<b>McGuire Woods Investment Conference</b>	Chicago, IL	02/23/11
<b>iBIO IndEx Finals</b>	Chicago, IL	02/15/11
<b>PMWC</b>	Mountainview, CA	01/18/11
<b>PROPEL - Sikich Business Development Presentation</b>	Chicago, IL	11/04/10
<b>Innovate Illinois</b>	Chicago, IL	10/26/10
<b>Springboard Enterprises ATLS</b>	New York, NY	10/21/10
<b>Springboard Enterprises</b>	Wellesley, MA	06/02/10
<b>NU Innovation Day</b>	Chicago, IL	05/18/10
<b>Michigan Growth Capital</b>	Ypsilanti, MI	05/11/10
<b>Bio2010 Business Forum</b>	Chicago, IL	05/03/10
<b>iBio PROPEL Finals</b>	Chicago, IL	04/08/10
<b>Invest Midwest Symposium</b>	St. Louis, MO	03/24/10

\* To be confirmed

**About the Company:**

Ohmx is advancing e-Diagnostics by developing a home monitoring device that can quantify clinical biomarkers and other important disease indicators from a finger prick. Ohmx's handheld monitoring device is electronic, low-cost, user-friendly, contains advanced communications protocols and can be used as a near-patient analyzer in the convenience of the patient's home. Except for diabetes, there are few consumer devices that can monitor chronic diseases. Ohmx systems address this unmet need by offering a comprehensive platform for tests routinely used for chronic disease monitoring, including cardiac markers, blood gases, electrolytes, metabolites, lipids, cholesterol, glucose, glycosylated serum proteins and hemoglobin. Ohmx was founded by NU Prof. Thomas Meade, PhD, who sold his prior company to Motorola for \$300MM; President & CEO is Barbara Dyson and R&D is headed by Dimitra Georganopoulou, PhD (Inverness, Nanosphere). Ohmx seeks to raise \$8.3MM to fund manufacturing, product launch and commercialization. The Company has raised \$11.1MM to date.

*This press release contains forward-looking statements that involve a number of risks and uncertainties. Our actual results could differ materially from the results identified or implied in any forward-looking statement. These statements are based on our views as of the date they are made with respect to future results or events. The Company does not undertake to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results or events expressed or implied therein will not be realized.*